MedPath

CRioablation vs Antiarrhythmic Drugs for Persistent Atrial Fibrillation Trial (CRAFT)

Phase 1
Conditions
Recurrent Persistent Atrial Fibrillation
MedDRA version: 20.0Level: LLTClassification code 10071667Term: Persistent atrial fibrillationSystem Organ Class: 100000004849
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
EUCTR2017-004202-18-ES
Lead Sponsor
Fundación Interhospitalaria para la Investigación Cardiovascular
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
196
Inclusion Criteria

Patients with recurrent persistent AF
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 166
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

• Patients with AF for more than one year at baseline
• FA prior ablation
• Age> 75 years or <18 years
• Hyperthyroidism
•Hypertrophic cardiomyopathy
• Severe valvular disease (stenosis or regurgitation)
• Carriers of cardiac valves
• AP Diameter of AI> 50 mm (left parasternal long axis)
• Contraindications for anticoagulation
• Left atrial thrombus
• Anemia
• Active infection
• Pregnancy
• FA secondary to transient, avoidable or correctable causes (hyperthyroidism, pneumonia, pulmonary embolism, drugs, hydroelectrolytic alterations ...)
• Life expectancy of less than 24 months
• Participation in another non-purely observational study
• Patients unable to understand treatment and / or study and / or providing adequate informed consent
• Any condition, that in the opinion of the physician responsible for the patient, contraindicates any of the treatments of the study

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath